Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study

Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study / Lugaresi, A.; Durastanti, V.; Gasperini, C.; Lai, M.; Pozzilli, C.; Orefice, G.; Sotgiu, Stefano; Pucci, E.; Ardito, B.; Millefiorini, E.; the CoSa Study, Group. - In: CLINICAL NEUROPHARMACOLOGY. - ISSN 0362-5664. - 31:3(2008), pp. 167-172. [10.1097/wnf.0b013e3181571a8e]